Tags : Recurrent Clostridium difficile


Finch Therapeutics’ CP101 Receives FDA’s Breakthrough Therapy Designation (BT) for

Shots: The FDA’s BT designation follows P-II PRISM3 study results assessing CP101 vs PBO in patients with recurrent C. difficile FDA’s BT designation is granted to the drugs showing clinical improvement over currently available therapy in serious or life-threatening conditions on at least one clinically significant endpoint with benefits of Priority Review and accelerated approval […]Read More